Updates on the Management of CINV From the 2014 June

Congresses

Program Goals

Introduction

Introduction (cont)

3 Major Classes of Antiemetic Agents Used in CINV Prevention

Antiemetic Guidelines: Current Recommendations

NK-1 RAs: Aprepitant

Investigational NK-1 RAs

Investigational NK-1 RAs (cont)

Aprepitant vs Metoclopromide in Delayed CINV

Rolapitant in Patients Receiving MEC

Phase 3 Study Design

Rolapitant in Patients Receiving MEC

Efficacy Results

Rolapitant in Patients Receiving MECSafety

Rolapitant in Patients Receiving HEC

Study Design of 2 Phase 3 RCTs

Rolapitant in Patients Receiving HEC

Efficacy Results

NEPA: A Fixed Dose Oral Combination of Netupitant and

PalonosetronPrimary End Point Efficacy Results From 3 RCTs

NEPA + DEX vs Oral PALO + DEX in AC-based MEC

Multinational, Randomized, Double-blind Phase 3 Study

NEPA + DEX vs Oral PALO + DEX in AC-based MEC

Overall CR Rates Across Multiple Cycles

NEPA + DEX vs PALO + DEX in AC-Based MEC

Safety Across Multiple Cycles

NEPA + DEX vs PALO + DEX in AC-based MEC

Most Common TRAEs Across Multiple Cycles

Non-AC MEC

NEPA in Multicycle MEC and HECPhase 3 Study Design

NEPA in Multicycle MEC and HECPatient Baseline and Disease Characteristics

NEPA in Multicycle MEC and HEC Post-Hoc Analysis of No Emesis Rates (Cycle 1) in

Patients Receiving Carboplatin

Fosaprepitant in Non-AC MECPhase 3 Study Design

APF530 vs Palonosetron

Aprepitant in Pediatric PatientsPhase 3 Study Design

The Problem of Nausea

Summary

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)